Trial · NCT00522925

A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

NCT00522925, Phase 2, Completed, Ligand Pharmaceuticals; results first posted 2011-09-14

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension. Trials, record NCT00522925. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00522925

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension
NCT number: NCT00522925
Status: Completed
Phases: Phase 2
Enrollment: 280 participants, actual
Lead sponsor: Ligand Pharmaceuticals
Conditions: Hypertension
Interventions: PS433540, placebo, PS433540
First posted: 2007-08-30
Last updated: 2011-09-16
Results first posted: 2011-09-14

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame
Primary	Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure	4 weeks of treatment with PS43540
Secondary	Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure	4 weeks of treatment with PS43540
Secondary	Change From Baseline in Mean Seated Systolic and Diastolic Blood Pressure	4 weeks of treatment with PS43540

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure	4 weeks of treatment with PS43540	mmHg	MEAN
SECONDARY	Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure	4 weeks of treatment with PS43540
SECONDARY	Change From Baseline in Mean Seated Systolic and Diastolic Blood Pressure	4 weeks of treatment with PS43540

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure	1- Placebo	-0.3	95% Confidence Interval -4.8 to 4.2	mmHg
Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure	2- PS433540 200mg	-11.9	95% Confidence Interval -15.3 to -8.6	mmHg
Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure	3- PS433540 500mg	-15.3	95% Confidence Interval -18.8 to -11.8	mmHg

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	1- Placebo	36
Overall Study	STARTED	2- PS433540 200mg	39
Overall Study	STARTED	3- PS433540 500mg	38
Overall Study	COMPLETED	1- Placebo	28
Overall Study	COMPLETED	2- PS433540 200mg	38
Overall Study	COMPLETED	3- PS433540 500mg	36
Overall Study	NOT COMPLETED	1- Placebo	8
Overall Study	NOT COMPLETED	2- PS433540 200mg	1
Overall Study	NOT COMPLETED	3- PS433540 500mg	2

Source ClinicalTrials.gov

Adverse events42

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Upper Respiratory Tract Infection	Infections and infestations	1- Placebo	1	36	1
other	Upper Respiratory Tract Infection	Infections and infestations	2- PS433540 200mg	1	39	1
other	Upper Respiratory Tract Infection	Infections and infestations	3- PS433540 500mg	1	38	1
other	Headache	Nervous system disorders	1- Placebo	4	36	6
other	Headache	Nervous system disorders	2- PS433540 200mg	2	39	2
other	Headache	Nervous system disorders	3- PS433540 500mg	3	38	4
other	Fatigue	General disorders	1- Placebo	1	36	1
other	Fatigue	General disorders	2- PS433540 200mg	2	39	2
other	Fatigue	General disorders	3- PS433540 500mg	0	38	0
other	Back Pain	Musculoskeletal and connective tissue disorders	1- Placebo	3	36	3

1 to 10 of 42Source ClinicalTrials.gov

See all 42 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	1- Placebo
Total, all-cause mortality	2- PS433540 200mg
Total, all-cause mortality	3- PS433540 500mg
Total, other adverse events	1- Placebo	9	36
Total, other adverse events	2- PS433540 200mg	8	39
Total, other adverse events	3- PS433540 500mg	10	38
Total, serious adverse events	1- Placebo	1	36
Total, serious adverse events	2- PS433540 200mg	1	39
Total, serious adverse events	3- PS433540 500mg	0	38

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00522925

GET https://conductscience.org/api/trials/v1/NCT00522925/events?page=2

API reference For AI assistants